[ad_1] SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to […]
Tag: Nektar Therapeutics
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
[ad_1] SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar’s Board of Directors granted non-qualified stock options to purchase an aggregate of 18,310 […]
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
[ad_1] Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports […]
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
[ad_1] SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London. Jefferies Global […]
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
[ad_1] 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) […]
